



TSX-V: QPT

A Biotechnology Company Developing and Commercializing Products to Improve Quality of Life

Quest has 5 independent business units under its umbrella

- Each brings unique technologies to enhance shareholder value
- Operating under their own management, clinical team and Board

Major Focus on the treatment of cancer

- OncoQuest - Antibody Based Combination Immunotherapy
- OncoCare Therapeutics - Targeted Cancer Therapy
- OncoVent - China Joint Venture for Immunotherapy

Other individual business units focus on other pharmaceutical applications

- Madenco Biosciences – Dermatological and wound healing applications
- Bioceltran – Transdermal Delivery (PTD) Technology and Photodynamic Therapy Technology

TSX-Venture Exchange Listed	Symbol: QPT
Year Founded	1996
Year Listed	1999
Share Capital	\$ 35.6 M
Licensing Fees to Date	\$ 9.6 M
Shares Outstanding	167 M
Options Outstanding	19 M
Shareholder Base	South Korea 42% Canada 25% China 17% US 3% Europe 7 % Insiders 6%

Recent News

Jul 20, 2018

Madenco Biosciences Announces Strategic Decision to Drop Consumer Health Products and Focus on Pharmaceutical Product Development

Jun 01, 2018

Abstract Describing Use of Oregovomab in Pancreatic Cancer to be Published in JCO as Part of ASCO 2018 Meeting

May 14, 2018

Dr. Eliel Bayever Joins OncoQuest as Chief Medical Officer

Feb 12, 2018

OncoQuest to Present at BIO CEO & Investor Conference

Feb 06, 2018





OncoQuest Completes US \$6 Million Private Placement

Jan 03, 2018

Madenco Biosciences Announces Licensing Agreement for Patented EGF Wound Healing Technology

Nov 14, 2017

OncoQuest Announces Presentation of Pre-Clinical Data from its IgE Based Immunotherapy Platform Technology at the 32nd Annual Society for Immunotherapy of Cancer (SITC)

	Business Units	Highlights	Quest Ownership Info
Cancer Therapies	 OncoQuest	Three different combinatorial immunotherapy clinical trials are underway for the treatment of ovarian cancer with oregovomab Her2/neu IgE preclinical development for metastatic breast cancer	46.2%
	 OncoVent	Anti-MUC1 MAB AR 20.5 for pancreatic cancer development in China	11 %
	OncoCare Therapeutics	Novel targeted therapy (truncated MUC-16) development for cancer in collaboration with UNMC	45 %
Other Pharm Products	 MADENCO	Dermatology and wound healing products based on proprietary transdermal delivery technologies	82 %
	 BIOCELTRAN	New drug development based on Photodynamic Therapy or Protein Transduction Technology	20 %

Why Quest PharmaTech?

- Unique Business Model with Five Strategic Business Units
- Multiple Products in the Clinic
- Diversified Product Pipeline
- Well Financed to meet Milestones
- Creating shareholder value with unique therapies and technologies
- Experienced management team
- Global network of collaborators and Investors (US, Korea, Europe and China)
- Extensive patent portfolio
- Considerable scientific and clinical publications in peer reviewed journals



TSX-V: QPT

A Biotechnology Company Developing and Commercializing Products to Improve Quality of Life

Quest Scientific Advisory Board Members

Dr. Chris Nicodemus (Chair)
President & CSO, AIT Strategies, US

Dr. Michael A Hollingsworth, Ph.D.
Professor, Eppley Institute, University of Nebraska Medical Center, US

Dr. Eric Shi, Ph.D.
Professor, Nanjing Medical University & Associate Dean, Academy of Clinical & Translational Research, Jiangsu Province

Dr. Ki-Jun Hwang, Ph.D.
Director of Centre for Research in Bioactive Materials, Chonbuk National University, Korea

Dr. Ronald Moore, M.D., Ph.D., FRCSC
Cross Cancer Institute, University of Alberta Hospital, Edmonton, Canada

OFFICERS AND DIRECTORS

Dr. Madi R. Madiyalakan, Ph.D.
CEO and Director

Mr. Lorne Meikle, B.A
Chairman, Director

Mr. W. John Meekison, CPA, CMA, P. Log, CIM
Director

Mr. J. Mark Lievonen, C.M., FCPA, FCA, BBA, MBA, LLD
Director

Mr. Shawn Lu, CIM, M. Finan.
Director

Mr. Pierre Vermette, CPA
Chief Financial Officer

CONTACT INFORMATION

Dr. Madi R. Madiyalakan, CEO
(780) 448-1400 ext.204
madi@questpharmatech.com



- developing next generation of combinatorial immunotherapy products for the treatment of cancer
- Positive interim results from Phase II clinical study of lead product (oregovomab) with excellent safety profile provides path to a product registration trial
- Initiated antibody manufacturing program to support planned registration trial and commercial use.
- Diversified product pipeline covering almost all cancers that kill, and a novel product class that may qualify for breakthrough designation (IgE). Potential optimization in combination with chemotherapy, immuno-stimulants and checkpoint inhibition
- A China based global pharmaceutical company as major investor and development partner, Hepalink USA



- Joint Venture with Shenzhen Hepalink Pharmaceutical Co., Ltd
- Focus on development of combination immunotherapy for the China market
- Initiated anti-MUC1 MAb AR20.5 manufacturing for Phase II study in pancreatic cancer
- Leverage additional resources to accelerate worldwide Antibody Manufacturing and Clinical Development Strategy

OncoCare Therapeutics

- Novel approach for targeted cancer therapy using a combinatorial approach for optimal efficacy
- Lead product (MAb AR9.6) under development is for a novel target (MUC 16) for cancer therapy discovered at University of Nebraska Medical Center
- Second product (ACP2127) under development is a multi-functional inhibitor combining the



- Focused on development of scientifically validated pharmaceutical products through development, licensing and acquisition
- Product categories include dermatology and wound healing
- Products based on proprietary transdermal delivery technology licensed from Bioceltran (SP Technology)



- Quest owns Photodynamic Therapy Technology and Bioceltran owns Protein Transduction Domain (PTD) Technology
- Quest and Bioceltran are developing skin penetrating active molecules for pharmaceutical use
- Quest has worldwide (excluding South Korea) rights to Bioceltran PTD Technology and Products for certain indications
- Bioceltran has exclusive license to Quest's Photodynamic Therapy Technology